Therapure Ranks No. 115 On The 2017 PROFIT 500 – Its 4th Consecutive Year On The List

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Canadian Business and PROFIT recently ranked Therapure Biopharma Inc. (“Therapure” or the “Company”) No. 115 on the 29th annual PROFIT 500, the definitive ranking of Canada’s Fastest-Growing Companies. Published in the October issue of Maclean’s magazine and at CanadianBusiness.com, the PROFIT 500 ranks Canadian businesses by their five-year revenue growth.

Therapure made the 2017 PROFIT 500 list with a five-year revenue growth of 613%. Of the manufacturing companies on the list with more than 100 employees, Therapure ranked

• Third by five-year revenue growth, and
• Third largest employer in Canada.

Therapure is a fully integrated Contract Development and Manufacturing Organization (CDMO) whose people have the scientific and technical expertise to successfully deliver at every stage of product development (preclinical, clinical and commercial).

“It is never easy to earn a spot on the PROFIT 500, but this year’s applicant pool was the most competitive yet,” says Deborah Aarts, PROFIT 500 program manager. “This year’s winners demonstrate the resilience, innovation and sheer management smarts it takes to build a thriving business today. Canada—and the world—needs more entrepreneurial success stories like these.”

“Therapure is honoured to be in the PROFIT 500 ranking for a fourth consecutive year,” says President and CEO Nick Green. “This achievement reflects on our people’s passion, responsiveness and commitment to developing and manufacturing biotherapeutics that improve patient care. Further, with the strategic acquisition of our CDMO business, Therapure is now in a stronger position to grow here in Canada.”

Therapure was also the recipient of the CMO Leadership Individual Attribute Awards in March 2017.

About the PROFIT 500 For 29 years, the PROFIT 500 has been Canada’s most respectable and influential ranking of entrepreneurial achievement. Developed by PROFIT and now published in Maclean’s magazine and at CanadianBusiness.com, the PROFIT 500 ranks Canadian companies on five-year revenue growth. For more information on the ranking visit PROFIT500.com or CanadianBusiness.com.

About Canadian Business
Founded in 1928, Canadian Business is the longest-serving and most-trusted business publication in the country. It is the country’s premier media brand for executives and senior 5 business leaders. It fuels the success of Canada’s business elite with a focus on the things that matter most: leadership, innovation, business strategy and management tactics. Learn more at CanadianBusiness.com.

About Therapure Biopharma Inc.
Therapure Biopharma Inc. is an integrated biopharmaceutical company focused on complex biological therapeutics and technologies that can provide new options for patient care. Therapure Biopharma Inc. has two divisions: Therapure Biomanufacturing and its product division comprised of Therapure Biologics (plasma derived product) and Therapure Innovations (drug discovery and product development).

Therapure Biopharma Inc. operates out of two facilities located in Mississauga, Ontario: a 130,000-square foot cGMP facility that includes biomanufacturing, research and quality control laboratories and is built to meet FDA (US), HPFB (Canada), EMA (Europe) and MHRA (UK) standards, and a new 43,000 square foot facility housing 30,000 square feet of cGMP warehouse. For more information on Therapure Biopharma Inc., please visit www.therapurebio.com.

About Therapure Biomanufacturing
Therapure Biomanufacturing is a global contract development and manufacturing organization (CDMO) offering integrated services for developing, manufacturing, purifying and packaging complex biological therapeutics. Its scientific and manufacturing expertise, as well as its flexible state-of-the-art cGMP facility, provide clients with optimal biomanufacturing solutions to advance their biotherapeutics from discovery to market. For more information on Therapure Biomanufacturing, please visit www.therapurebio.com/CDMO.